Glioblastoma, the agressive form of brain cancer, doesn’t just attack the brain — it also eats away at the skull, thinning bones and reshaping the immune hideouts inside them.
Researchers discovered this surprising effect in mouse models and confirmed it in people with the disease, where tumors trigger bone loss far from the cancer site. Their new study, published in Nature Neuroscience, also shows how blocking this erosion might backfire, speeding up tumor growth and sabotaging immunotherapy.
Abhishek Dubey and colleagues stumbled onto this while exploring how brain tumors mess with the body’s immune system. Glioblastoma is notorious for dodging treatments by hijacking immune cells, but the team wondered about the skull marrow — a newly recognized stash of immune reserves that funnels cells to the brain during injury or disease. Using two mouse glioma models, one more aggressive and “mesenchymal” like many human cases, they scanned skulls with high-resolution imaging.
The scans revealed tumors sparking bone resorption, slashing density and thickness at suture edges where bones fuse in adulthood. Erosion hit hardest in the occipital bone, distant from the tumor, kicking off early, just 10 days post-implant in the fiercer model. Unlike strokes or skin-deep tumors, only brain cancers triggered this, even mineralizing inside the growth itself. Channels linking skull marrow to the brain’s lining ballooned in number and size, potentially easing immune traffic.
Human data echoed this: CT scans from 26 glioblastoma patients showed thinner skulls at key spots like the lambda and mid-occipital compared to matched controls with no tumors. It wasn’t tied to cancer size or spot, hinting at a systemic signal.
Diving deeper with single-cell RNA sequencing, the team mapped immune shifts in skull versus leg bone marrow. In healthy skulls, B cells dominate, but tumors flipped the script; neutrophils exploded twofold, while B cells plunged 60-94%. Skull marrow revved up inflammatory pathways; leg marrow dialed them down. Flow cytometry confirmed that tumors boosted proliferating immune cells in skulls, amping antigen presentation but also exhaustion markers.
The twist came with treatments. Drugs like zoledronic acid or anti-RANKL—FDA-approved for osteoporosis—halted skull erosion in mice. But in the mesenchymal model, they fueled faster tumor spread and wiped out the anti-PD-L1’s survival boost. Why? They cut activated T cells while letting inflammatory neutrophils, which shield tumors, rebound.
This warns against bone-protecting meds for glioblastoma patients, especially in immunotherapy trials. It spotlights the skull as an overlooked player in cancer’s immune games, urging fresh strategies to harness rather than hinder its changes.
Journal References: Dubey, Abhishek, et al. “Brain Tumors Induce Widespread Disruption of Calvarial Bone and Alteration of Skull Marrow Immune Landscape.” Nature Neuroscience. doi: 10.1038/s41593-025-02064-4
